BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 14595509)

  • 1. p53, estrogen and progesterone receptors in diagnostic curettage for endometrial adenocarcinoma and their correlation with morphological data and disease stage at hysterectomy.
    Bonfitto VL; de Angelo Andrade LA
    Sao Paulo Med J; 2003 Jul; 121(4):163-6. PubMed ID: 14595509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do estrogen, progesterone, P53 and Ki67 receptor ratios determined from curettage materials in endometrioid-type endometrial carcinoma predict lymph node metastasis?
    Gülseren V; Kocaer M; Özdemir İA; Çakır İ; Sancı M; Güngördük K
    Curr Probl Cancer; 2020 Feb; 44(1):100498. PubMed ID: 31395281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial.
    Trovik J; Wik E; Werner HM; Krakstad C; Helland H; Vandenput I; Njolstad TS; Stefansson IM; Marcickiewicz J; Tingulstad S; Staff AC; ; Amant F; Akslen LA; Salvesen HB
    Eur J Cancer; 2013 Nov; 49(16):3431-41. PubMed ID: 23932335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Relationships between the molecular biomarkers and the clinicopathologic features and prognosis in endometrial carcinoma].
    Yao YY; Xu WZ; Wang Y; Shen DH; Wang JL; Wei LH
    Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Oct; 43(5):743-8. PubMed ID: 22008688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma.
    Stelloo E; Nout RA; Naves LC; Ter Haar NT; Creutzberg CL; Smit VT; Bosse T
    Gynecol Oncol; 2014 May; 133(2):197-204. PubMed ID: 24556061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
    Lax SF; Pizer ES; Ronnett BM; Kurman RJ
    Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature.
    Kounelis S; Kapranos N; Kouri E; Coppola D; Papadaki H; Jones MW
    Mod Pathol; 2000 Apr; 13(4):379-88. PubMed ID: 10786803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.
    Huvila J; Talve L; Carpén O; Edqvist PH; Pontén F; Grénman S; Auranen A
    Gynecol Oncol; 2013 Sep; 130(3):463-9. PubMed ID: 23777659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma.
    Oreskovic S; Babic D; Kalafatic D; Barisic D; Beketic-Oreskovic L
    Gynecol Oncol; 2004 Apr; 93(1):34-40. PubMed ID: 15047211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification.
    Guan J; Xie L; Luo X; Yang B; Zhang H; Zhu Q; Chen X
    J Gynecol Oncol; 2019 Jan; 30(1):e13. PubMed ID: 30479097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accuracy of preoperative curettage in determining tumor type and grade in endometrial cancer.
    Thanachaiviwat A; Thirapakawong C; Leelaphatanadit C; Chuangsuwanich T
    J Med Assoc Thai; 2011 Jul; 94(7):766-71. PubMed ID: 21774280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selected immuno-histochemical markers in curettage specimens and their correlation with final pathologic findings in endometrial cancer patients.
    Obeidat BR; Matalka II; Mohtaseb AA; Al-Kaisi NS
    Pathol Oncol Res; 2013 Apr; 19(2):229-35. PubMed ID: 23055021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium.
    Halperin R; Zehavi S; Habler L; Hadas E; Bukovsky I; Schneider D
    Eur J Gynaecol Oncol; 2001; 22(2):122-6. PubMed ID: 11446475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
    Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
    Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical comparison of uterine papillary serous and papillary endometrioid carcinoma: clues to pathogenesis.
    Demopoulos RI; Mesia AF; Mittal K; Vamvakas E
    Int J Gynecol Pathol; 1999 Jul; 18(3):233-7. PubMed ID: 12092593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of p53 in imprint smears of endometrial carcinoma.
    Kosmas K; Stamoulas M; Marouga A; Kavantzas N; Patsouris E; Athanassiadou P
    Diagn Cytopathol; 2014 May; 42(5):416-22. PubMed ID: 24167025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical analysis of p53 protein over-expression in endometrial carcinomas: inverse correlation with sex steroid receptor status.
    Koshiyama M; Konishi I; Wang DP; Mandai M; Komatsu T; Yamamoto S; Nanbu K; Naito MF; Mori T
    Virchows Arch A Pathol Anat Histopathol; 1993; 423(4):265-71. PubMed ID: 8236823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance and diagnostic value of PTEN and p53 expression in endometrial carcinoma. A retrospective clinicopathological and immunohistochemical study.
    Daniilidou K; Frangou-Plemenou M; Grammatikakis J; Grigoriou O; Vitoratos N; Kondi-Pafiti A
    J BUON; 2013; 18(1):195-201. PubMed ID: 23613406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L-type amino acid transporter 1 expression increases in well-differentiated but decreases in poorly differentiated endometrial endometrioid adenocarcinoma and shows an inverse correlation with p53 expression.
    Watanabe J; Yokoyama Y; Futagami M; Mizunuma H; Yoshioka H; Washiya K; Hana K; Endou H; Okayasu I
    Int J Gynecol Cancer; 2014 May; 24(4):659-63. PubMed ID: 24694899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The significance of Wilms Tumor Gene (WT1) and p53 expression in curettage specimens of patients with endometrial carcinomas.
    Matalka I; Obeidat B; Mohtaseb A; Awamleh A
    Pathol Res Pract; 2013 Jan; 209(1):19-23. PubMed ID: 23207289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.